AB0698 EFFECTIVENESS AND SAFETY OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN REAL-WORLD CLINICAL PRACTICE IN EUROPE: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL 12-MONTH COHORT STUDY
Published: Jun 1, 2019
Abstract
Background
Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-TNF with an established efficacy and safety profile in axial spondyloarthritis (axSpA) in clinical trial settings.1Objectives
To report CZP effectiveness and safety in patients (pts) with axSpA, including ankylosing spondylitis (AS; radiographic axSpA) and non-radiographic (nr-) axSpA subpopulations, in routine clinical practice in Europe....Paper Details
Title
AB0698 EFFECTIVENESS AND SAFETY OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN REAL-WORLD CLINICAL PRACTICE IN EUROPE: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL 12-MONTH COHORT STUDY
Published Date
Jun 1, 2019
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History